Popular terms

Bowel topics
Bowel Disease
Inflammatory Bowel Disease
Irritable Bowel Syndrome
Inflammation
Mercaptopurine
Probiotics
Abdominal Pain
Discomfort
Bowel Movement
Gastrointestinal
Ulcerative Colitis
Rheumatoid Arthritis
Jejunal Tube
Spring Mechanism
Small Bowel

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Bowel patents



      

This page is updated frequently with new Bowel-related patent applications.




Date/App# patent app List of recent Bowel-related patents
07/14/16
20160200789 
 Il4 conjugated to antibodies against extracellular matrix components patent thumbnailIl4 conjugated to antibodies against extracellular matrix components
A conjugate comprising interleukin-4 (il4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting il4 to tissues in vivo.
Philogen S.p.a.


07/14/16
20160200766 
 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders patent thumbnailAgonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorder, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.


07/14/16
20160199410 
 Oral rehydration solution patent thumbnailOral rehydration solution
Provided herein are oral rehydration compositions useful for treating a dehydrated subject. Exemplary compositions provided herein are oral rehydration compositions customized for use with children, athletes, and subjects having short bowel syndrome.
Mayo Foundation For Medical Education And Research


07/14/16
20160199052 
 Organ retractor patent thumbnailOrgan retractor
A medical device of the present invention includes one or more anchors and an elongated member. Advantageously, the elongated member may be coupled to the anchors.

07/14/16
20160199020 
 Bowel sound analysis method and system patent thumbnailBowel sound analysis method and system
A bowel sound analysis method and system utilizes an audio collection apparatus to continuously monitor an abdominal cavity of an examinee and collect a bowel sound signal of an intestinal tract inside the abdominal cavity, converts the bowel sound signal into a digital signal, then removes noise from the digital signal by using higher-order statistics (hos) and captures a high-complexity feature from the digital signal by using fractal dimension algorithm, and subsequently defines the high-complexity feature as an intestinal motility signal. The refore, according to the intestinal motility signal, a time point when intestinal motility occurs in the intestinal tract inside the abdominal cavity of the examinee can be learned, and bowel sound features such as the amplitude, frequency, and period of the intestinal motility signal may further be analyzed to determine a health condition of the intestinal tract..
Chimei Medical Center


07/14/16
20160198935 
 Apparatus and  fixing and shortening bowel at the time of endoscopy patent thumbnailApparatus and fixing and shortening bowel at the time of endoscopy
Disclosed are a device and method for fixing and shortening the bowel at the time of endoscopy. The device and method can improve the shortening efficiency of the bowel when compared with the existing endoscope surgery, reduce the inspection time, and mitigate patient inconvenience.

07/07/16
20160193469 
 Neuromodulation system and related methods patent thumbnailNeuromodulation system and related methods
Embodiments of the present invention describe a system and method of stimulating nerves during a medical procedure including positioning one or more electrodes in electrical contact with one or more nerves of a patient and electrically stimulating the one or more nerves during a lower urinary, rectal or medical procedure affecting the bowel sufficient to affect one or more of bladder activity, prostate function, incontinence, or pain.. .
Urologix, Llc


07/07/16
20160193343 
 Composition for use in treating and preventing inflammation related disorder patent thumbnailComposition for use in treating and preventing inflammation related disorder
The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (ha) or ha mixture, whereas the ha or the ha mixture as a delivery vehicle can be a formulation including at least two has having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), crohn's disease, irritable bowel syndrome (ibs), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis..
Aihol Corporation


07/07/16
20160193268 
 Andrographis paniculata extract patent thumbnailAndrographis paniculata extract
An extract of andrographis particulata extract containing andrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographolide, neoandrographolide, polysaccharides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease..
Nutrition Science Partners Limited


07/07/16
20160193180 
 Composition for preventing and treating immune diseases containing daurinol compound as active ingredient patent thumbnailComposition for preventing and treating immune diseases containing daurinol compound as active ingredient
The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of il-17 and tnf-α, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive t cells and increasing regulatory t cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the mongolian medicinal plant haplophyllum dauricum or haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases..
The Catholic University Of Korea Industry-academic Cooperation Foundation


07/07/16
20160193169 

Compositions and methods for treating intestinal hyperpermeability


The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

06/30/16
20160185849 

Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease


Multiple-variable dose methods for treating tnfα-related disorders, including crohn's disease and psoriasis, comprising administering tnfα inhibitors, including tnfα antibodies, are described. Multiple-variable dose methods include administration of a tnf-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the tnf-inhibitor is administered in a higher dosage during the induction phase..

06/23/16
20160178644 

Methods for diagnosing and treating inflammatory bowel disease


Biomarkers for diagnosing inflammatory bowel disease, including crohn's disease, including fibrotic or fibrostenotic crohn's disease, and ulcerative colitis and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and crohn's disease, including fibrotic or fibrostenotic crohn's disease, are provided..

06/23/16
20160177306 

Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field


The invention relates to antisense oligonucleotidic sequences (odn) against smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as crohn's disease and ulcerative colitis.. .

06/23/16
20160176816 

Novel biphenyl derivative and preparing same


The present invention provides novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, methods for preparing the same, and a pharmaceutical composition containing the same. The novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, as disclosed in the present invention, act as muscarinic m3 receptor antagonists, and thus are useful for the prevention or treatment of a disease selected from the group consisting of chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes..

06/23/16
20160175491 

Local drug delivery devices and methods for treating cancer


Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site..

06/23/16
20160175382 

Compositions and methods for inducing urinary voiding and defecation


Methods, pharmaceutical formulations, and kits are provided for using neurokinin 2 receptor agonists to effectuate voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing voiding of urine and defecation in mammals that do not have a voiding dysfunction such as, for example, in a person who is comatose and may void unconsciously or in a pet at a convenient location at a specific time.

06/23/16
20160175368 

Legume/grain based food product with prebiotic/probiotic source


A minimally processed ready-to-eat legume/grain product is provided containing a significant amount of probiotic fiber and a probiotic source or is consumed with a probiotic source for the prevention and/or treatment of inflammatory chronic conditions such as inflammatory, autoimmune chronic conditions such as irritable bowel syndrome (ibs), digestive disorders such chronic constipation, gastric acid reflux, diabetes, heart disease, obesity, some type of cancer, malabsorptive disorders, eczema as well mental health disorders such as anxiety disorder. The present invention is suitable for men and woman of all ages..

06/23/16
20160175253 

Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and preparation thereof


The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.. .

06/16/16
20160168201 

Methods and compositions for the treatment of gastrointestinal disorders


Compositions and related methods for treating ibs and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (gerd), duodenogastric reflux, crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase c (gc-c) receptor..
Ironwood Pharmaceuticals, Inc.


06/16/16
20160166602 

Food supplement composition


A dietary supplement for promoting increased vitality, supporting mood, improving heart health, improving immune strength, improving antioxidant balance, protecting against free radical damage, improving bowel function, and enhancing flavonoid intake. The composition is a combination of cacao, chia seeds, green tea, cinnamon, ginger and turmeric in specific percents of the formulation.
Homeland Housewares, Llc


06/16/16
20160166599 

Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient


The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine n1-oxide or a derivative thereof as an effective ingredient.. .
Hayashibara Co., Ltd.


06/16/16
20160166587 

Amelioration of intestinal fibrosis and treatment of crohn's disease


Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or crohn's disease involve administering a therapeutic amount of card-024 or related compound.. .
The Regents Of The University Of Michigan


06/16/16
20160166576 

Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)


This invention relates to amidopyrazole compounds that are inhibitors of interieukin receptor-associated kinases, in particular irak-4, and are useful in the treatment of cellular proliferative diseases. Speifically (5-methylpyridin-2-yl)-1 h-pyrazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives are disclosed for use in the method of treating inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and cancer..
Merck Sharp & Dohme Corp.


06/09/16
20160161503 

Diagnostic method


The invention relates to a method of diagnosing or assessing an inflammatory bowel disease in a subject, comprising comparing the level of one or more markers in a tissue or body fluid of the subject relative to a reference value for the one or more markers, wherein the marker is selected from the group consisting of secretogranin-1 or a fragment thereof, guanylin or a fragment thereof, spp 24 or a fragment thereof, ambp or a fragment thereof; and serglycin or a fragment thereof.. .
Sydney Local Health District


06/09/16
20160161501 

Novel inflammatory bowel disease markers and therapies for colitis-associated intestinal fibrosis


Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof.
The Regents Of The University Of California


06/09/16
20160159790 

Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof


This invention concerns pyrroloquinoline derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, parkinson's disease, huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, irritable bowel syndrome.
Universite De Montpellier


06/09/16
20160158303 

Method of extracting flavonoids and/or polyphenols from dried and powdered citrus peels, compositions therefrom, and methods of treatment of diseases associated with chronic inflammation


Improved processes for extracting polyphenols and/or flavonoids from citrus peels are provided that comprise 1) heating a ground peel to form a pre-treated, ground peel; and 2) extracting the compounds of interest from the pre-treated, ground peel using a basic solution of ph greater than 7 and less than 12. Such processes serve to increase the efficiency of extraction of the polyphenols and/or flavonoids.
Tait Laboratories Inc.


06/09/16
20160158262 

Methods of treating irritable bowel syndrome


The present invention provides a method for treating irritable bowel syndrome (ibs) in a subject in need thereof. The treatment can include administering about 550 mg of rifaximin three times per day and about 500 mg of neomycin two times per day for 14 days to the subject to treat the ibs.
Cedars-sinai Medical Center


06/02/16
20160153041 

Detection and treatment of irritable bowel syndrome


Methods are disclosed herein for identifying a subject with irritable bowel syndrome (ibs). Methods are also disclosed for determining if an agent is effective for the treatment or prevention of ibs.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


06/02/16
20160152699 

Pan-elr+ cxc chemokine antibodies


Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company


06/02/16
20160151449 

Use of tight junction antagonists to treat inflammatory bowel disease


The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents.
Alba Therapeutics Corporation


06/02/16
20160151340 

Bowel cleansing composition


A bowel cleansing composition includes as a first cleansing ingredient, a specific sugar alcohol such as xylitol, sorbitol, etc., as a second cleansing ingredient glycerol, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, and polyglycitol, as a second cleansing ingredient ascorbic acid or a mixture of ascorbic acid and a salt of ascorbic acid, as a third cleansing ingredient picosulfate, and an aqueous solvent, wherein the concentration of the first cleansing ingredient is 10 g/l to 500 g/l based on the total composition, the concentration of the second cleansing ingredient is 15 g/l to 500 g/l based on the total composition, the concentration of the third cleansing ingredient is 1 mg/l to 100 mg/l based on the total composition, and the volume of the aqueous solvent is 0.1 l to 1.0 l.. .

05/26/16
20160145694 

Method for detecting methylation of colorectal cancer specific methylation marker gene for colorectal cancer diagnosis


The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker gpm6a (nm_201591, glycoprotein m6a) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis..
Genomictree, Inc.


05/26/16
20160145306 

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases


The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease.. .
Protagonist Therapeutics, Inc.


05/26/16
20160145289 

Compounds and methods for treating bacterial infections


The present invention encompasses compounds and methods for treating and preventing bacterial infections specifically urinary tract infections and those caused by bacteria containing type 1 pili and fimh. The present invention also encompasses compounds and methods for treating inflammatory bowel disease specifically crohn's disease..
Washington University


05/26/16
20160145249 

Alxr agonist compound


The present invention provides a compound having alxr agonist activity. Specifically, the invention provides a compound having alxr agonist activity represented by general formula (i) wherein all the symbols are as defined in the specification, a salt thereof, a solvate thereof, or a prodrug thereof as well as an agent containing the same as an active ingredient for preventing and/or treating an alxr-associated disease, such as an inflammatory bowel disease, an autoimmune disease, a chronic inflammatory disease, asthma, pulmonary fibrosis, atopic dermatitis, ischemia-reperfusion injury, myocardial infarction, or alzheimer's disease..
Ono Pharmaceutical Co., Ltd.


05/26/16
20160145206 

N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use


The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (copd); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as behçet's disease.
Pimco 2664 Limited


05/26/16
20160143965 

Bacteriophage therapy


The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive escherichia coli strain thereby treating the subject.
Institut Pasteur


05/26/16
20160143940 

Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems


Psa is delivered to the host by outer membrane vesicles (omvs), secretion structures that target bacterial molecules to host cells. Purified omvs direct the in vitro differentiation of functional tregs with potent suppressive activity in a psa dependent manner.
California Institute Of Technology


05/26/16
20160143723 

Implantable digestive tract organ


An implantable digestive organ is provided for the transport of materials through the digestive tract and in one particular application to an artificial large bowel for replacing all or part of a colon. The prosthetic organ of one embodiment includes an outer support structure, an expandable member or members located within the support structure, and a flexible inner member forming a conduit for passage of material.
Python Medical, Inc.




Bowel topics: Bowel Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Inflammation, Mercaptopurine, Probiotics, Abdominal Pain, Discomfort, Bowel Movement, Gastrointestinal, Ulcerative Colitis, Rheumatoid Arthritis, Jejunal Tube, Spring Mechanism, Small Bowel

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.1286

5403

0 - 1 - 107